Copenhagen, Denmark
Onsite/Online

ESTRO 2022

Session Item

Monday
May 09
10:30 - 11:30
Poster Station 2
20: Head and neck
Annett Linge, Germany
3280
Poster Discussion
Clinical
Risk factors for the development of maxillary osteoradionecrosis in ACC patients treated with CIRT
Sara Ronchi, Italy
PD-0828

Abstract

Risk factors for the development of maxillary osteoradionecrosis in ACC patients treated with CIRT
Authors:

Barbara Vischioni1, Stefania Russo1, Martino Meuli1, Sara Ronchi1, Rossana Ingargiola1, Alexandra Ferent2, Sara Imparato3, Lorenzo Preda4, Mario Ciocca2, Maria Bonora2, Silvia Molinelli2, Ester Orlandi2

1CNAO National Center for Oncological Hadrontherapy, Clinical Depatment, Pavia, Italy; 2CNAO National Center for Oncological Hadrontherapy, Clinical Department, Pavia, Italy; 3CNAO National Center for Oncological Hadrontherapy, Radiology Department, Pavia, Italy; 4San Matteo Hospital, Radiology Department, Pavia, Italy

Show Affiliations
Purpose or Objective

The present study aims to evaluate dosimetric and clinical risk factors for the development of maxillary osteoradionecrosis (ORN) in head and neck adenoid cystic carcinoma (ACC) patients treated with carbon ion radiotherapy (CIRT).

Material and Methods

Clinical data and treatment plans of ACC patients, consecutively treated from January 2013 to October 2016 within the phase II clinical trial CNAO S9/2012/C, were retrospectively reviewed. ORN and other treatment-related toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTACE) scale. The maxillary bone was contoured on the planning CT, and only patients receiving more than 10% of the prescription dose at their maxilla were considered for the analysis (67 patients). The volumes of maxilla receiving doses from 10 Gy (RBE) to 60 Gy (RBE) (VD), with an increment of 10 Gy (RBE), and additional clinical factors were correlated to the incidence of ORN with univariate analysis (Chi-square test). The Cox regression model was subsequently applied for multivariate analysis. Treatment plans calculated with a local effect model (LEM) –based optimization were recalculated with the modified microdosimetric kinetic model (MKM), and compared with literature data from the Japanese experience.

Results

The median time interval from the start of CIRT to ORN appearance was 24 months (range, 8 - 48 months). Maxillary ORN was observed in 11 patients (16%). Grade 1 ORN was observed in 2 patients (18%), G2 in 3 (27%), G3 in 4 (36%) and G4 in 2 patients (18%). At univariate analysis, the presence of maxillary elements within the PTV and acute mucositis correlated with the development of maxillary ORN. VD were significantly higher for all dose levels tested in patients with maxillary ORN than in patients without (Figure1), according to both radiobiological models. At multivariate analysis V50 significantly correlated with ORN. 





Conclusion

The volume of maxilla irradiated with high dose values was relevant for the ORN development in our ACC patients’ cohort. These results were in line with the previously published data obtained with a different radiobiological model. Our finding might be helpful to prevent ORN risk in patients receiving CIRT.